Cloning And Expression Of Chronic Myeloid Leukemia Bcr-abl Fusion Gene And Its Immunization To Induce Cytotoxic T Lymphocyte

With an annual incidence of about one in 100.000 people, chronic myeloid leukemia (CML) is a malignant disorder of the hematopoietic stem cell, accounting for 20% of all cases of leukemia.The common symptoms are asthenia, weight loss, sweating, and the discovery of an abdominal mass(the spleen).The Philadelphia chromosome (Ph) — the cytogenetic hallmark of CML, found in at least 95 percent of cases, is a shortened chromosome 22 that arises from a reciprocal translocation, t(9;22)(q34;q11),which gives origin to a hybrid bcr-abl oncogene, encoding a p210-BCR-ABL fusion protein with elevated tyrosine kinase and transforming activities. Most clinic and laboratary reserch provided direct evidence that bcr-abl is probabaly the main cause of CML, and this fusion gene is the main target in the gene therapy for CML.So far, there is no effective treatment for CML. Most patients present with a chronic phase for about 2-3 years, and then ineviterbly transform...